59只个股今日获机构买入型评级，万华化学最新评级被调高，13股机构首次关注。 证券时报·数据宝统计显示，今日机构研报共发布79条买入型评级记录，共涉及59只个股。万华化学关 注度最高，共获6次机构买入型评级记录。 今日获机构买入型评级个股中，共有19条评级记录中对相关个股给出了未来目标价。以公布的预测目标 价与最新收盘价进行对比显示，共有11股上涨空间超20%，海康威视上涨空间最高，8月12日东方证券 预计公司目标价为43.00元，上涨空间达47.01%，上涨空间较高的个股还有锦波生物、万华化学等，上 涨空间分别为43.57%、43.08%。 从机构评级变动看，今日机构买入型评级记录中，有13条评级记录为机构首次关注，涉及并行科技、丰 茂股份等13只个股。 市场表现方面，机构买入型评级个股今日平均上涨1.21%，表现强于沪指。股价上涨的有31只，涨停的 有光库科技等。涨幅居前的有三鑫医疗、协创数据、工业富联等，今日涨幅分别为14.24%、11.29%、 9.24%。跌幅较大的个股有煌上煌、奥比中光、锦波生物等，跌幅分别为9.97%、5.80%、5.33%。 | 688677 | 海泰新光 | 1 | 5.83 ...

2025 年 8 月 12 日 公司研究 销售费用大幅增长，影响 Q2 利润表现 ——锦波生物（832982.BJ）2025 年半年报点评 买入（维持） 当前价：320.03 元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 分析师：吴子倩 执业证书编号：S0930525070004 021-52523872 wuziqian@ebscn.com 市场数据 | 总股本(亿股) | 1.15 | | --- | --- | | 总市值(亿元)： | 368.26 | | 一年最低/最高(元)： | 114.21/451.74 | | 近 3 月换手率： | 59.22% | 股价相对走势 -12% 49% 111% 173% 235% 08/24 11/24 02/25 05/25 锦波生物 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -13.93 | -12.01 | 115.34 | | 绝对 | -11.32 | -6. ...

Core Viewpoint - JINBO Biopharmaceutical (832982.BJ) reported strong growth in its 2025 semi-annual report, with significant increases in revenue and net profit, alongside a substantial rise in R&D expenses, indicating a focus on innovation and market expansion [1][2][8]. Financial Performance - As of June 30, 2025, JINBO Biopharmaceutical achieved an operating revenue of approximately 859 million yuan, representing a year-on-year growth of 42.43% [2]. - The company recorded a net profit attributable to shareholders of approximately 392 million yuan, reflecting a year-on-year increase of 26.65% [2]. - The gross profit margin remained above 90%, specifically at 90.68%, earning the company the nickname "Little Moutai" on the Beijing Stock Exchange [2]. Revenue Growth Drivers - The increase in operating revenue was primarily driven by growth in medical devices and functional skincare products [3]. - Medical device revenue growth was mainly attributed to the sales of implant products based on recombinant human collagen [4]. - Functional skincare products saw a remarkable revenue increase of approximately 121 million yuan, up 152.39% year-on-year, indicating significant scale effects [5]. R&D Investment - JINBO Biopharmaceutical's R&D expenses reached 45.7962 million yuan, a substantial increase of 85.43% compared to the previous year, accounting for 5.33% of operating revenue [8]. - The rise in R&D spending was largely due to increased collaboration with institutions like Peking University and higher costs associated with clinical trials [9]. Market Performance - Since the beginning of 2025, JINBO Biopharmaceutical's stock has experienced a continuous upward trend, with a year-to-date increase of 101.92%, reaching a peak of 452.29 yuan per share on May 22 [12]. - The current price-to-earnings ratio (TTM) stands at 46.06, with a total market capitalization of approximately 36.824 billion yuan [12]. Institutional Interest - The semi-annual report revealed that several institutions and public funds have increased their holdings in JINBO Biopharmaceutical during the first half of the year [14]. - Notably, CITIC Securities became the eighth largest shareholder after acquiring 782,390 shares, while two funds from Ping An Bank and China Merchants Bank also increased their stakes [15][16].

证券之星消息，8月12日医疗美容板块较上一交易日上涨0.16%，*ST美谷领涨。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 1803.13万 | 5.27% | 900.06万 | 2.63% | -2703.19万 | -7.89% | | 000615 *ST美谷 | 639.16万 | 13.49% | -212.57万 | -4.49% | -426.59万 | -9.00% | | 300896 爱美客 | -176.08万 | -0.27% | 1005.58万 | 1.57% | -829.50万 | -1.29% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流入2266.21万元，游资资金净流入1693.07万元，散户 资金 ...

Core Viewpoint - The demand slowdown is impacting Jinbo Biological, the first stock of recombinant collagen on the Beijing Stock Exchange, as evidenced by its recent financial performance and stock price decline [1][3]. Financial Performance - In the first half of 2025, Jinbo Biological reported revenues of 859 million yuan and a net profit attributable to shareholders of 392 million yuan, representing year-on-year growth of 42.43% and 26.65% respectively [1]. - However, the revenue growth rate has significantly slowed, with a 48 percentage point decrease compared to the same period in 2024, marking the first time since its listing in July 2023 that revenue growth fell below 40% [1]. Product Performance - The slowdown in performance is primarily attributed to the decline in sales of its medical device product "Wei Yimei," which is based solely on recombinant collagen [3]. - In the first half of 2025, Wei Yimei generated 645 million yuan in revenue, with a year-on-year growth of 34.7%, a drop of over 70 percentage points compared to the same period in 2024 [3]. Market Strategy - In July 2023, Jinbo Biological partnered with Meituan to promote Wei Yimei through a "100 billion subsidy" initiative, which has led to a significant drop in terminal prices [5]. - The price for new customers in Beijing for Wei Yimei has decreased by over 40% compared to the previous year's subsidized price, with subsequent prices dropping by more than 70% from the original guidance [5]. Growth in Other Segments - Despite the slowdown in the medical beauty segment, Jinbo Biological's cosmetics revenue is experiencing high growth, with functional skincare brands like "Zhongyuan" and "ProtYouth" generating 121 million yuan in the first half of 2025, a year-on-year increase of 152% [5]. Strategic Partnerships - Jinbo Biological has engaged with Zhong Shanshan's Yangshengtang to establish a broader sales promotion system, leveraging Yangshengtang's extensive distribution network through its subsidiary Nongfu Spring [6][7]. - This partnership is expected to enhance market penetration for Jinbo Biological's skincare brands, although it may challenge the valuation scarcity of Jinbo Biological as a supplier in the medical beauty sector [7]. Valuation Comparison - Currently, Jinbo Biological's price-to-earnings (PE) ratio is around 40 times, while leading A-share cosmetics company Proya has a PE ratio of approximately 20 times [8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a revenue of 860 million yuan in H1 2025, representing a year-on-year increase of 42.4%, with a net profit of 390 million yuan, up 26.7% year-on-year [7] - The sales of medical device products remained stable, while functional skincare products saw significant growth, with revenue from medical devices, functional skincare, and raw materials reaching 710 million, 120 million, and 30 million yuan respectively in H1 2025, reflecting year-on-year growth of 33.4%, 152.4%, and 12.4% [7] - The company launched the world's first injectable gel product in April 2025, which is expected to drive domestic growth [7] - Strategic partnerships are being strengthened to accelerate international expansion, with plans to recruit partners in Thailand for medical device distribution [7] - The long-term growth outlook remains positive, with adjusted net profit forecasts for 2025-2027 being 1.04 billion, 1.46 billion, and 1.86 billion yuan respectively [7] Financial Summary - Total revenue is projected to reach 2.10 billion yuan in 2025, with a year-on-year growth rate of 45.81% [1] - The company's net profit is expected to grow to 1.04 billion yuan in 2025, reflecting a growth rate of 42.09% [1] - The latest diluted EPS is forecasted to be 9.04 yuan per share in 2025, with a P/E ratio of 35.39 [1]

Group 1 - The company Jinbo Biological (832982) announced a semi-annual report distribution plan, proposing a cash dividend of 10 yuan per share (including tax), with a total cash dividend distribution expected to be 115 million yuan [2] - The semi-annual report indicates that the company's operating revenue for the first half of the year was 859 million yuan, representing a year-on-year increase of 42.43%, while net profit reached 392 million yuan, up 26.65% year-on-year, with earnings per share of 3.41 yuan and a weighted average return on equity of 23.01% [2] - The company's core business focuses on the research, development, production, and sales of high-end implant-grade medical devices using type A recombinant human collagen as the main raw material [2] Group 2 - As of the end of the first half of the year, the total number of shareholders in the company was 8,543, an increase of 3,868 shareholders compared to the previous quarter, reflecting a growth rate of 82.74% [2] - The latest closing price of the stock was 320.03 yuan, with a cumulative increase of 0.06% over the past five days and a total turnover rate of 7.22% [2] - In terms of institutional ratings, three institutions have rated the stock as a buy in the past month, with the highest target price estimated by Guotai Haitong at 435.03 yuan, as reported on July 23 [2]

Core Viewpoint - Jinbo Biological (832982) reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company achieved operating revenue of 859 million yuan, representing a year-on-year increase of 42.43% [1] - The net profit attributable to shareholders reached 392 million yuan, reflecting a year-on-year growth of 26.65% [1] Dividend Distribution - The company plans to distribute a cash dividend of 10 yuan (including tax) for every 10 shares to all shareholders, amounting to a total cash dividend payout of 115 million yuan [1]

（文章来源：证券日报） 证券日报网讯 8月11日晚间，锦波生物发布公告称，公司第四届监事会第八次会议审议通过了《关于公 司2025年半年度报告及摘要的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，锦波生物发布公告称，公司第四届董事会第十三次会议审议通过了《关于 公司2025年半年度报告及摘要的议案》等多项议案。 ...